| Q84041835 | Association between OPG, RANK and RANKL gene polymorphisms and susceptibility to acute coronary syndrome in Korean population |
| Q84958377 | Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients |
| Q37024429 | Association between osteoprotegerin gene polymorphisms and cardiovascular disease in type 2 diabetic patients |
| Q48353042 | Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients |
| Q30477731 | Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension |
| Q94594156 | Associations of Bone Turnover Markers with Cognitive Function in Patients Undergoing Hemodialysis |
| Q38824466 | Atorvastatin Reduces Circulating Osteoprogenitor Cells and T-Cell RANKL Expression in Osteoporotic Women: Implications for the Bone-Vascular Axis |
| Q46535201 | Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome |
| Q24623768 | Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality |
| Q38889423 | Bone loss and vascular calcification: A bi-directional interplay? |
| Q37728708 | Bovine lactoferrin improves bone mass and microstructure in ovariectomized rats via OPG/RANKL/RANK pathway |
| Q33867461 | Can Brain Natriuretic Peptides and Osteoprotegerin Serve As Biochemical Markers for the Detection of Aortic Pathology in Children and Adolescents with Turner Syndrome? |
| Q58715301 | Circulating osteogenic proteins are associated with coronary artery calcification and increase after myocardial infarction |
| Q37300823 | Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis |
| Q35019922 | Consolidated and emerging inflammatory markers in coronary artery disease |
| Q64113486 | DeepTACT: predicting 3D chromatin contacts via bootstrapping deep learning |
| Q38832148 | Deletion of a Distal RANKL Gene Enhancer Delays Progression of Atherosclerotic Plaque Calcification in Hypercholesterolemic Mice. |
| Q83770424 | Epidemiology of osteoporosis |
| Q36357434 | Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension |
| Q34464362 | High incidence of Aggregatibacter actinomycetemcomitans infection in patients with cerebral infarction and diabetic renal failure: a cross-sectional study |
| Q51769795 | Immunologic response enhances atherosclerosis-type 1 helper T cell (Th1)-to-type 2 helper T cell (Th2) shift and calcified atherosclerosis in Bacillus Calmette-Guerin (BCG)-treated apolipoprotein E-knockout (apo E-/-) mice. |
| Q36156920 | Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis |
| Q40719297 | Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6. |
| Q38018808 | Inflammatory cytokines in heart failure: mediators and markers |
| Q51119015 | Investigation of OPG/RANK/RANKL Genes as a Genetic Marker for Cardiac abnormalities in Thalassemia Major Patients. |
| Q33695937 | Myocardial Perfusion in Rheumatoid Arthritis Patients: Associations with Traditional Risk Factors and Novel Biomarkers |
| Q38034388 | Osteoporosis--a risk factor for cardiovascular disease? |
| Q50059262 | Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial |
| Q60668215 | Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes |
| Q34234163 | Osteoprotegerin as a marker of atherosclerosis: a systematic update |
| Q41513500 | Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants |
| Q50127068 | Osteoprotegerin concentration is associated with the presence and severity of peripheral arterial disease in type 2 diabetes mellitus |
| Q34852319 | Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jκ/Msx2 signaling pathway |
| Q36295418 | Osteoprotegerin levels in ST-elevation myocardial infarction: Temporal profile and association with myocardial injury and left ventricular function |
| Q37310825 | Osteoprotegerin, vascular calcification and atherosclerosis |
| Q35995048 | Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients |
| Q51337112 | Osteoprotegerin/sRANKL Signaling System in Pulmonary Sarcoidosis: A Bronchoalveolar Lavage Study. |
| Q46224491 | Oxidized LDL level is related to gene expression of tumour necrosis factor super family members in children and young adults with familial hypercholesterolaemia |
| Q51371948 | Plasma osteoprotegerin levels and long-term prognosis in patients with intermediate coronary artery lesions. |
| Q36942224 | Prospective association between inflammatory markers and progression of coronary artery calcification in adults with and without type 1 diabetes |
| Q64944581 | RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain. |
| Q37727115 | RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-α. |
| Q39673708 | Receptor Activator of Nuclear Factor κB Ligand Is a Novel Inducer of Tissue Factor in Macrophages |
| Q37155840 | Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients |
| Q39859050 | Relationships of OPG Genetic Polymorphisms with Susceptibility to Cardiovascular Disease: A Meta-Analysis. |
| Q55318421 | Selective inhibition of receptor activator of NF-κB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction. |
| Q46798854 | Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus |
| Q37997644 | TNF revisited: osteoprotegerin and TNF-related molecules in heart failure |
| Q46339783 | TNFRSF11B gene polymorphisms increased risk of peripheral arterial occlusive disease and critical limb ischemia in patients with type 2 diabetes |
| Q37494039 | TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases. |
| Q38703771 | Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification |
| Q39240586 | The collagen cross-linking enzyme lysyl oxidase is associated with the healing of human atherosclerotic lesions |
| Q36470227 | The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? |
| Q36686037 | The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease |
| Q37922640 | The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review |
| Q38056541 | The role of osteoprotegerin in cardiovascular disease |
| Q37625670 | Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies |
| Q46567372 | Treatment with anti-RANKL antibody reduces infarct size and attenuates dysfunction impacting on neutrophil-mediated injury |
| Q37805514 | Tumor necrosis factor superfamily molecules in acute coronary syndromes |
| Q36521118 | Unique Distal Enhancers Linked to the Mouse Tnfsf11 Gene Direct Tissue-Specific and Inflammation-Induced Expression of RANKL. |
| Q36931445 | Vascular calcification: pathophysiology and clinical implications |